PHONE: 517.536.8210
FAX: 517.536.8205


TransPharm Preclinical Solutions TransPharm Preclinical Solutions TransPharm Preclinical Solutions TransPharm Preclinical Solutions


April 2012

President’s Letter:

TransPharm has given me some wonderful opportunities over the last 4 years. Locally, we volunteer for Junior Achievement, Big Brothers/Big Sisters, and donate to numerous charities that I wouldn’t have been able to do in the past.

At the state level, we were awarded as one of the Top 50 Companies to Watch in Michigan in 2011. I was invited to a business round table discussion and met with Jennifer Granholm, Michigan’s outgoing Governor. In the last two months, I was invited to Governor Rick Snyder’s residence in Lansing for the Moores River Drive Breakfast. Both events brought together many of the States business leaders and gave us a chance to meet with many of our States representatives and hear some of the new initiatives that are in the works for small business owners.

Read More

January 2012

President’s Letter: Let me be the last person to wish you a Happy New Year! 2011 proved to be a year full of challenges and rewards for us here at TransPharm. We have had many requests to run in vivo models of pathogens we have not yet validated. While it’s nearly impossible to have data in hand for all the possible requests we could see, we are now fully committed to putting more resources into new project validations. TransPharm has many new models that we plan to roll out in 2012 and Dr. Lopez will touch on a few of those below. Marci Peek, our Contract & Protocol Specialist, will also inform you of some news regarding our product, the Final Report. We closed the year with a 15% increase in revenue over 2010, making it our best year to date. This is one reason TransPharm will be making new commitments to our clients in 2012. Our pricing structure will remain untouched, new models will be rolled out and our new Final Report Guarantee are just a few ways we are saying thank you for your business. Dan TransPharm is going viral! The year 2012 promises many exciting projects for the Research and Development team here at TransPharm! One of these projects involves the expansion of our current models of infection to now include viral models, namely Herpes Simplex Virus (HSV) types 1 and 2. With the various clinical manifestations of this pathogen and its worldwide spread, we believe HSV is a logical entry point into the viral infection modeling realm. TransPharm is currently in the process of developing and validating both an in vitro model to detect early viral mRNA transcripts as well as an in vivo sepsis model of HSV infection. We have also laid the groundwork to explore the murine model of latency and reactivation of all herpes viruses. Another area of research we are excited about is the development of a mouse model for malaria infections (Plasmodium falciparum). Being the world’s second biggest killer (just behind tuberculosis) and with relatively little research going into anti-malaria medications, TransPharm believes this model will aid in the search for cost-effective treatments for this deadly disease. So stay tuned...

Read More